Learn more about our current news, views and updates
For any media enquiries please contact CEO Matt Regan: m.regan@micreos.com
06/02/2024
The unique design of MEndoB makes this an invaluable Precision Antimicrobial for combatting staphylococci, including antimicrobial resistant strains such as methicillin-resistant S. aureus (MRSA). MEndoB could address a wide range of conditions where staphylococcal species have caused an imbalance or disruption to the normal microbial community in or on the human body
Read More11/01/2024
Today, the University of Copenhagen shared the positive results of an investigational study, published in Blood providing ground-breaking evidence that Staphylococcus aureus and its toxins induce drug resistance in malignant T-cells against therapeutics such as HDAC inhibitors and chemotherapies commonly used for cutaneous T cell lymphoma (CTCL). Importantly, the study shows that bacterial killing by Micreos engineered, S. aureus-targeting endolysin countered this drug-resistance effect.
Read More07/03/2023
Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression.
Read More01/03/2023
Since its founding in 2005, Micreos has become a world leading developer of endolysin and phage technology, enabling the targeted killing of only unwanted bacteria while protecting the rest of the Microbiome.
Read More25/10/2022
Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.
Read More18/10/2022
Dr. Matthew Dunne, Dr. Samuel Kilcher and Dr. Anja Keller join us from the Swiss Federal Institute of Technology (ETH Zurich), with the goal of developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.
Read More14/04/2022
Zug, Switzerland, 14 April 2022 — Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in selectively targeting and killing the harmful Staphylococcus aureus bacterial pathogen while maintaining a healthy microbiome and preventing antimicrobial resistance (AMR).
Read More05/04/2022
Zug, Switzerland, 5-April 2022 — Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer.
Read More14/10/2021
The Hague, October 14, 2021 - Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland.
Read More30/09/2021
THE HAGUE, The Netherlands, 30 September, 2021 - Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria.
Read More